Alector, Inc. (NASDAQ:ALEC) Given Consensus Rating of “Hold” by Brokerages

Alector, Inc. (NASDAQ:ALEC) has received a consensus rating of “Hold” from the eight research firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $3.25.

A number of brokerages recently issued reports on ALEC. Morgan Stanley reiterated an “underweight” rating on shares of Alector in a report on Thursday, January 8th. William Blair lowered Alector from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 22nd. Mizuho set a $1.50 price objective on shares of Alector and gave the stock a “neutral” rating in a research note on Wednesday, October 22nd. BTIG Research raised shares of Alector from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Finally, Cantor Fitzgerald cut Alector from an “overweight” rating to a “neutral” rating in a research report on Wednesday, October 22nd.

Insider Activity

In other news, CEO Arnon Rosenthal sold 104,347 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $1.12, for a total transaction of $116,868.64. Following the completion of the transaction, the chief executive officer directly owned 2,420,040 shares of the company’s stock, valued at approximately $2,710,444.80. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sara Kenkare-Mitra sold 41,687 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $1.12, for a total value of $46,689.44. Following the completion of the sale, the insider owned 501,652 shares in the company, valued at approximately $561,850.24. This represents a 7.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 196,104 shares of company stock worth $220,064. 9.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Alector

A number of hedge funds and other institutional investors have recently modified their holdings of ALEC. Jane Street Group LLC boosted its stake in shares of Alector by 4.7% in the 1st quarter. Jane Street Group LLC now owns 256,551 shares of the company’s stock valued at $316,000 after purchasing an additional 11,618 shares during the last quarter. Strs Ohio bought a new position in shares of Alector during the 1st quarter valued at about $126,000. Vanguard Personalized Indexing Management LLC increased its holdings in Alector by 49.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 52,095 shares of the company’s stock worth $73,000 after purchasing an additional 17,170 shares in the last quarter. TD Asset Management Inc lifted its position in shares of Alector by 483.3% in the second quarter. TD Asset Management Inc now owns 651,738 shares of the company’s stock worth $912,000 after purchasing an additional 540,000 shares in the last quarter. Finally, FNY Investment Advisers LLC grew its position in Alector by 100.0% in the second quarter. FNY Investment Advisers LLC now owns 20,000 shares of the company’s stock valued at $28,000 after purchasing an additional 10,000 shares in the last quarter. Institutional investors and hedge funds own 85.83% of the company’s stock.

Alector Price Performance

Shares of ALEC opened at $1.98 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.76 and a current ratio of 3.76. The firm has a market cap of $216.12 million, a PE ratio of -1.85 and a beta of 0.64. The firm’s 50 day moving average price is $1.74 and its 200 day moving average price is $2.01. Alector has a twelve month low of $0.87 and a twelve month high of $3.40.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.